Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,419 active trials60 approved drugs271 evidence items
- OncoTree
- LNM
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,886 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,374)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02348216 | Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma(ZUMA-1) | completed | Phase 1 / Phase 2 | 307 | Kite, A Gilead CompanyINDUSTRY | 6 | Jun 4, 2024 | clinicaltrials |
| NCT03430011 | Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma(EVOLVE) | completed | Phase 1 / Phase 2 | 165 | Juno Therapeutics, a Subsidiary of CelgeneINDUSTRY |
| 1 |
| May 24, 2024 |
| clinicaltrials |
| NCT03184194 | Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide | completed | Phase 2 | 62 | Amsterdam UMC, location VUmcOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT04164368 | Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients | completed | Phase 2 | 67 | Fudan UniversityOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT04438005 | A Study of ICP-022 in Patients With R/R DLBCL(DLBCL) | completed | Phase 2 | 3 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | May 13, 2024 | clinicaltrials |
| NCT02728102 | Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401) | completed | Phase 2 | 203 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | May 7, 2024 | clinicaltrials |
| NCT04942730 | Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)(FluBuBe) | completed | Phase 2 | 50 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT01597219 | Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers(UK-Haplo) | completed | Phase 2 | 77 | University College, LondonOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT01979536 | Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma | completed | Phase 2 | 137 | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2024 | clinicaltrials |
| NCT00888927 | Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma | completed | Phase 1 / Phase 2 | 42 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT01063907 | A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 95 | Kyowa Kirin Co., Ltd.INDUSTRY | 3 | Apr 25, 2024 | clinicaltrials |
| NCT01226472 | Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001 | completed | Phase 2 | 1 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT01626664 | KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) | completed | Phase 2 | 71 | Kyowa Kirin, Inc.INDUSTRY | 6 | Apr 25, 2024 | clinicaltrials |
| NCT02445248 | Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients(JULIET) | completed | Phase 2 | 115 | Novartis PharmaceuticalsINDUSTRY | 10 | Apr 18, 2024 | clinicaltrials |
| NCT03797456 | A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL) | completed | Phase 2 | 111 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Apr 18, 2024 | clinicaltrials |
| NCT03246750 | B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell Lymphoma | completed | Phase 1 / Phase 2 | 34 | The Thai Lymphoma Study GroupOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT02100423 | Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 2 | 35 | Paolo Caimi, MDOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT00799513 | Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma(RV-NHL-PI351) | completed | Phase 2 | 48 | IRCCS San RaffaeleOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT03848845 | Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)(DREAMM 4) | completed | Phase 1 / Phase 2 | 41 | GlaxoSmithKlineINDUSTRY | 4 | Apr 9, 2024 | clinicaltrials |
| NCT02341014 | Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas | completed | Phase 1 / Phase 2 | 27 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT03310619 | A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies(PLATFORM) | completed | Phase 1 / Phase 2 | 62 | CelgeneINDUSTRY | 1 | Apr 4, 2024 | clinicaltrials |
| NCT03722147 | A Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 94 | AkesoINDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT04028115 | Bone Healing During Ninlaro Exposure(BONE) | completed | Phase 2 | 30 | Thomas LundOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT00596154 | Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma(PCNSL) | completed | Phase 2 | 33 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT02812706 | Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients(Islands) | completed | Phase 1 / Phase 2 | 36 | SanofiINDUSTRY | 1 | Apr 1, 2024 | clinicaltrials |
| NCT02891811 | Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy | completed | Phase 2 | 124 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 2 | Mar 29, 2024 | clinicaltrials |
| NCT03450057 | Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment(DARE) | completed | Phase 2 | 38 | Hellenic Society of HematologyOTHER | 1 | Mar 29, 2024 | clinicaltrials |
| NCT04052997 | Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma | completed | Phase 2 | 117 | ADC Therapeutics S.A.INDUSTRY | 11 | Mar 28, 2024 | clinicaltrials |
| NCT01897571 | Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL | completed | Phase 1 / Phase 2 | 400 | Epizyme, Inc.INDUSTRY | 10 | Mar 26, 2024 | clinicaltrials |
| NCT03056339 | Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies | completed | Phase 1 / Phase 2 | 49 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT04508647 | Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma | completed | Phase 2 | 4 | University of Colorado, DenverOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT02420912 | Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation | completed | Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT00877656 | HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma | completed | Phase 2 / Phase 3 | 21 | Emergent BioSolutionsINDUSTRY | 0 | Mar 18, 2024 | clinicaltrials |
| NCT02119468 | Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 32 | City of Hope Medical CenterOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT02636322 | Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib | completed | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT02926833 | Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)(ZUMA-6) | completed | Phase 1 / Phase 2 | 37 | Kite, A Gilead CompanyINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT00019097 | Vaccine Therapy in Treating Patients With Multiple Myeloma | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT02056756 | Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma | completed | Phase 1 / Phase 2 | 63 | Stichting European Myeloma NetworkNETWORK | 2 | Feb 20, 2024 | clinicaltrials |
| NCT04478123 | Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer | completed | Phase 2 | 62 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT02435849 | Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients(ELIANA) | completed | Phase 2 | 80 | Novartis PharmaceuticalsINDUSTRY | 11 | Feb 13, 2024 | clinicaltrials |
| NCT03155425 | PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma | completed | Phase 2 | 75 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 1, 2024 | clinicaltrials |
| NCT02653976 | A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | completed | Phase 2 | 67 | Solasia Pharma K.K.INDUSTRY | 4 | Jan 26, 2024 | clinicaltrials |
| NCT01190787 | Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone | completed | Phase 2 | 150 | European Myeloma Network B.V.NETWORK | 1 | Jan 23, 2024 | clinicaltrials |
| NCT03543813 | PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL | completed | Phase 1 / Phase 2 | 133 | CytomX TherapeuticsINDUSTRY | 4 | Jan 23, 2024 | clinicaltrials |
| NCT01858922 | Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A(TXCH-HD-12A) | completed | Phase 2 | 40 | Baylor College of MedicineOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT01991457 | Fludarabine / Total Body Irradiation Regimen for ALLO HCT in Acute Lymphoblastic Leukemia(FluTBI) | completed | Phase 2 | 19 | University of Alabama at BirminghamOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT03128359 | High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant | completed | Phase 2 | 38 | City of Hope Medical CenterOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT03506360 | Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | completed | Phase 2 | 13 | Mayo ClinicOTHER | 1 | Jan 9, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jun 4, 2024source: clinicaltrials